Lohmann Rauscher (LR): Personnel Change in Executive Board of LR

Food and Healthcare Press Releases Friday January 26, 2018 09:15
VIENNA and RENGSDORF, Germany--26 Jan--PRNewswire/InfoQuest

In January 2018, a change in the Executive Board of manufacturer and supplier of medical devices, Lohmann & Rauscher (L&R), took place after the former Chief Commercial Officer, Markus Sebastian, had resigned.

The Advisory Board and the CCO mutually agreed that Markus Sebastian is going to leave the Lohmann & Rauscher Corporate Group by the end of January 2018 to pursue new tasks and face new challenges.
Responsibility for the business unit Marketing & Sales will be assumed by Dipl.-Ing. Wolfgang Suessle, President & CEO, on a transitional basis.
Reprint free of charge - specimen copy requested
Lohmann & Rauscher Corporate Group

Lohmann & Rauscher (L&R) is a leading international supplier of high-quality medical devices and hygiene products ranging from conventional dressing material to modern treatment and nursing systems. Created in 1998 through the merger of Lohmann (founded in 1851) and Rauscher (founded in 1899), L&R has more than 160 years' expertise as a reliable solution provider for its customers.

With 4,600 employees, 44 corporate subsidiaries and shareholdings and more than 130 select partners, the company is active in all of the world's key markets. The L&R Group was able to realize a sales of EUR604,2 million in 2017. The L&R headquarters are located in Rengsdorf (Germany) and Vienna (Austria).

L&R's entrepreneurial spirit is reflected in the Group's claim of People.Health.Care.: the human, the health, and the care for both.
Further information on Lohmann & Rauscher (L&R) can be found at:
http://www.lohmann-rauscher.com
Press Contact:
Lohmann & Rauscher International GmbH & Co. KG
Public Relations
Sabrina Klein
Johann-Schorsch-Gasse 4 1140 Vienna
Tel.: +43-1-57670-386 Fax DW: 9386
E-Mail: Sabrina.Klein@at.LRmed.com
http://www.lohmann-rauscher.com
Source: Lohmann & Rauscher

Latest Press Release

Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

- Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research - Expands company's foundational CRISPR cutting and integration IP necessary to correct genetic defects in gene therapy patients - Merck to...

Kaneka officially starts continuous manufacturing under GMP

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Mamoru Kadokura) have installed continuous manufacturing equipment to be applied to pharmaceutical products at Kaneka Singapore Co. (Pte.) Ltd, (Headquarters: Singapore; President: Kazuhiko...

TIENS Group opens new high-tech Experience Store in Shenzhen

TIENS Group, one of leading corporations in the Healthcare industry, unveiled a new high-tech Customer Experience Store in Shenzhen. Li Jinyuan, founder and chairman of TIENS group, announced the official opening of its first store in the world on August...

Sotera Health#s Nordion completes the sale of its medical isotopes business to BWXT

- Nordion's increased focus on gamma technologies supports Sotera Health's company-wide commitment to Safeguarding Global Health(TM) Sotera Health LLC, the world's leading, fully integrated protector of global health, today announced the closing of the...

Menarini Ricerche to Sponsor Cancer Trial in Acute Myeloid Leukemia in USA

Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) AML in the USA has been transferred...

Related Topics